Published 2 days ago • loading... • Updated 1 day ago

Incyte's Skin Disease Drug Shows Long-Term Symptom Relief ...

On Saturday, Incyte announced 54-week Phase 3 data for povorcitinib, showing durable symptom relief in patients with moderate to severe hidradenitis suppurativa at the American Academy of Dermatology Annual Meeting in Denver.
Hidradenitis suppurativa affects up to 4% of the United States population, causing painful nodules and abscesses; only three FDA-approved treatments exist, including AbbVie's Humira, Novartis' Cosentyx, and UCB's Bimzelx.
Trial results showed up to 71.4% of patients achieved HiSCR50, while up to 57% reached HiSCR75 and up to 29% achieved HiSCR100. Povorcitinib also reduced inflammatory lesions, abscesses, and draining tunnels.
Regulatory applications for the oral JAK1 inhibitor are currently under review by the FDA and European Medicines Agency. Safety data showed the most frequent side effects were acne and upper respiratory infections, consistent with 24-week findings.
Pablo J. Cagnoni, Incyte's President and Global Head of Research and Development, stated the 54-week data provides "compelling" evidence for povorcitinib's potential to transform the HS treatment landscape as the first oral option.

Insights by Ground AI